You are here

Nonrestorative Sleep RSQ (Restorative Sleep Questionnaire) Development-- Methodology Study

Last updated on October 4, 2018

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Fountain Valley, California, 92708 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Nonrestorative Sleep
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-64 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects who self report nonrestorative sleep but no problems either getting to sleep
or staying asleep

- Complaints of significant distress or impairment in social, occupational, or other
important areas of functioning during daytime for at least 3 nights per week

- Self reports sWASO (Wake after sleep onset) for reports LPS (latency to persistent sleep onset ) for (then neither PSG (polysomnography) screening night showing WASO >45min, or LPS > 20
minutes)

- Customary bedtime betw. 9 pm and midnight and rise between 4 and 9 AM

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Psychiatric disease or disorder as determined by current administration of the MINI
(Mini International Neuropsychiatric Interview)

- History or presence of any breathing-related sleep disorder, narcolepsy, or any other
dyssomnias or any parasomnia, or restless legs syndrome MAP > 0.5 at screening

- History or presence of any medical or neurological condition that could interfere with
sleep (chronic pain, Restless leg, etc)

- Current use of meds wth known psychotropic effects or known or suspected effects on
sleep

- Alcohol or substance abuse (unless in remission for at least a year

- Excessive caffeine use (or any use after 6 pm for at least 3 months

- Regular napping or any naps after 6 pm

- Excessive cigarette or cigar smoking over the last 3 months

- no participation in an investigational new drug study within 30 days of screening, and
no previous participation in a study of PD200390

- No night or rotating shift work

NCT00705601
Pfizer
Terminated
Nonrestorative Sleep RSQ (Restorative Sleep Questionnaire) Development-- Methodology Study

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Excessive Daytime Sleepiness, Narcolepsy
NCT01006122
All Genders
18+
Years
Multiple Sites
Fibromyalgia, Sleep Disorders
NCT00883740
All Genders
18+
Years
Multiple Sites
Menopause, Hot Flashes, Sleep Disorders
NCT00256685
Females
Hot Flashes, Sleep Disorders
NCT00195520
Females
45+
Years
Multiple Sites
Nonrestorative Sleep RSQ (Restorative Sleep Questionnaire) Development-- Methodology Study
Refinement Of Patient Reported Outcomes Instruments In Subjects With Insomnia Characterized By Nonrestorative Sleep
To begin to refine development of the RSQ (Restorative Sleep Questionnaire) measure in subjects with NRS (Nonrestorative Sleep) by generating item content pertaining to morning refreshment and uncovering problems in instrument administration in subjects with nonrestorative sleep
Study was terminated on January 20, 2009 due to portfolio decision by Pfizer to discontinue further investigation of PD200390 for non-restorative sleep. The decision was not based on any safety concerns.
Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Nonrestorative Sleep
Procedure: PSG
PSG (polysomnography) for adaptation night, day 2 evening, and day 3 evening--used to identify suitable Nonrestorative Sleep candidates to participate in focus groups.
1
Intervention: Procedure: PSG
Drake CL, Hays RD, Morlock R, Wang F, Shikiar R, Frank L, Downey R, Roth T. Development and evaluation of a measure to assess restorative sleep. J Clin Sleep Med. 2014 Jul 15;10(7):733-41, 741A-741E. doi: 10.5664/jcsm.3860.


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
64
January 2009
January 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects who self report nonrestorative sleep but no problems either getting to sleep or staying asleep
  • Complaints of significant distress or impairment in social, occupational, or other important areas of functioning during daytime for at least 3 nights per week
  • Self reports sWASO (Wake after sleep onset) for <45 minutes for past 3 months, self reports LPS (latency to persistent sleep onset ) for <20 minutes for past 3 months (then neither PSG (polysomnography) screening night showing WASO >45min, or LPS > 20 minutes)
  • Customary bedtime betw. 9 pm and midnight and rise between 4 and 9 AM

Exclusion Criteria:

  • Psychiatric disease or disorder as determined by current administration of the MINI (Mini International Neuropsychiatric Interview)
  • History or presence of any breathing-related sleep disorder, narcolepsy, or any other dyssomnias or any parasomnia, or restless legs syndrome MAP > 0.5 at screening
  • History or presence of any medical or neurological condition that could interfere with sleep (chronic pain, Restless leg, etc)
  • Current use of meds wth known psychotropic effects or known or suspected effects on sleep
  • Alcohol or substance abuse (unless in remission for at least a year
  • Excessive caffeine use (or any use after 6 pm for at least 3 months
  • Regular napping or any naps after 6 pm
  • Excessive cigarette or cigar smoking over the last 3 months
  • no participation in an investigational new drug study within 30 days of screening, and no previous participation in a study of PD200390
  • No night or rotating shift work
Sexes Eligible for Study: All
18 Years to 64 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Canada,   United States
 
 
NCT00705601
A9001380
No
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
February 2011

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now